Single-cell and spatial transcriptomics identify immune-stromal interactions in cardiac allograft vasculopathy
Blocking a specific inflammation pathway with an existing drug significantly reduced coronary artery disease after transplant in mice, pointing to a first disease-modifying approach.
Single-cell RNA sequencing and spatial transcriptomics of human CAV coronary arteries revealed a distinct transcriptional signature dominated by modulated vascular smooth muscle cells and macrophage subsets that promote type 1 interferon-mediated inflammation in the neointima. Using a mouse model of CAV, IFN signaling blockade with ruxolitinib significantly reduced CAV incidence and prolonged allograft survival, identifying the JAK-STAT-IFN pathway as a viable therapeutic target for a condition that currently has no disease-modifying treatments.
What the study was
- Study design
- Multi-modal mechanistic study: single-cell RNA sequencing + spatial transcriptomics of human coronary arteries; mouse model with ruxolitinib pharmacological intervention
- Population
- Heart transplant recipients with cardiac allograft vasculopathy (CAV); compared to atherosclerotic CAD and non-diseased controls
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature Cardiovascular Research
Why it surfaced
Nature Cardiovasc Res publication. First mechanistic characterization of CAV using scRNA-seq + spatial transcriptomics with a clear therapeutic implication (ruxolitinib). CAV is the leading cause of death post-heart transplant with no targeted therapies. Mouse model validation supports translational potential. Evidence maturity capped at Exploratory (human mechanistic + animal model; no human trial yet).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.